GRIFOLS S A/S (NASDAQ:GRFS) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 2,944,231 shares, a drop of 37.6% from the September 28th total of 4,715,453 shares. Based on an average daily volume of 2,309,790 shares, the short-interest ratio is presently 1.3 days.
A number of hedge funds have recently made changes to their positions in GRFS. Suntrust Banks Inc. acquired a new stake in GRIFOLS S A/S in the first quarter valued at $252,000. Dynamic Technology Lab Private Ltd acquired a new stake in GRIFOLS S A/S in the first quarter valued at $285,000. Verition Fund Management LLC acquired a new stake in GRIFOLS S A/S in the first quarter valued at $324,000. Cubist Systematic Strategies LLC lifted its stake in GRIFOLS S A/S by 42.9% in the first quarter. Cubist Systematic Strategies LLC now owns 20,359 shares of the biotechnology company’s stock valued at $432,000 after acquiring an additional 6,115 shares during the last quarter. Finally, AMP Capital Investors Ltd acquired a new stake in GRIFOLS S A/S in the second quarter valued at $438,000. Hedge funds and other institutional investors own 21.05% of the company’s stock.
GRIFOLS S A/S stock opened at $19.44 on Friday. The firm has a market capitalization of $12.60 billion, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 1.29 and a beta of 1.21. GRIFOLS S A/S has a 1-year low of $17.47 and a 1-year high of $25.18. The company has a quick ratio of 1.12, a current ratio of 2.90 and a debt-to-equity ratio of 1.52.
GRFS has been the subject of a number of analyst reports. BidaskClub downgraded shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research report on Friday, July 13th. Zacks Investment Research raised shares of GRIFOLS S A/S from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 1st. Morgan Stanley decreased their target price on shares of GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating for the company in a research report on Monday, October 1st. UBS Group downgraded shares of GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 3rd. Finally, Berenberg Bank raised shares of GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. GRIFOLS S A/S has an average rating of “Hold” and a consensus target price of $21.50.
About GRIFOLS S A/S
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.